AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22382664 — intervention group
Group type: EXPERIMENTAL
Intervention: low-DEX (loading, 3 μg/kg/h for 10 min; maintenance, 0.2 μg/kg/h for 60 min)
Number of subjects: 12
Study 22382664 — intervention group
Group type: EXPERIMENTAL
Intervention: moderate-DEX (loading, 6 μg/kg/h for 10 min; maintenance, 0.4 μg/kg/h for 60 min)
Number of subjects: 12
Study 22382664 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 20170790 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide-guided, intensive patient management (BM)
Number of subjects: 278
Study 17590198 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mometasone furoate 0.1%
Number of subjects: 20
Study 17590198 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1%
Number of subjects: 20
Study 15770966 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m DTPA after dehydration (urine specific gravity > 1.025)
Number of subjects: 11
Study 15770966 — intervention group
Group type: COMPARATOR
Intervention: Tc-99m DTPA after adequate hydration (urine specific gravity < 1.010)
Number of subjects: 11
Study 15770966 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m MAG3 after dehydration
Number of subjects: 11
Study 15770966 — intervention group
Group type: COMPARATOR
Intervention: Tc-99m MAG3 after adequate hydration
Number of subjects: 11
Study 11913292 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Professional Whitestrips system (14 contact hours)
Number of subjects: 20
Study 11913292 — intervention group
Group type: COMPARATOR
Intervention: Nite White Excel 2 tray system (28 contact hours)
Number of subjects: 20
Study 9618736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (100 mg/kg b.w./24 h)
Number of subjects: 20
Study 9618736 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT2 genotype
Number of subjects: 20
Study 9618736 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT2 phenotype
Number of subjects: 20
Study 7621642 — intervention group
Group type: EXPERIMENTAL
Intervention: Light standard breakfast (Day A)
Number of subjects: 10
Study 7621642 — intervention group
Group type: COMPARATOR
Intervention: Heavy non‐standardized lunch (Day B)
Number of subjects: 10
Study 2116316 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine (100 mg oral)
Number of subjects: 12
Study 2116316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6995131 — intervention group
Group type: COMPARATOR
Intervention: Clofibate 0.5 g
Number of subjects: 10
Study 6995131 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate 0.2 g
Number of subjects: 10
Study 30730066 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver burden measured by Zarit Burden Interview
Number of subjects: 1020
Study 30730066 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQL) measured by EQ-5D-3L
Number of subjects: 1020
Study 30730066 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with services
Number of subjects: 1020
Study 28430947 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 33357
Study 28430947 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 33357
Study 28430947 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 33357
Study 28430947 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ECG LVH
Number of subjects: 33357
Study 26054890 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI > 25)
Number of subjects: 208
Study 26054890 — intervention group
Group type: COMPARATOR
Intervention: Nonobese patients
Number of subjects: 208
Study 26054890 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of LVM
Number of subjects: 208
Study 26054890 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of CMVR
Number of subjects: 208
Study 23681371 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative free tafluprost 0.0015%
Number of subjects: 38
Study 23681371 — intervention group
Group type: COMPARATOR
Intervention: Branded latanoprost 0.005%
Number of subjects: 38
Study 21220660 — intervention group
Group type: COMPARATOR
Intervention: Basic Internet (BI)
Number of subjects: 2005
Study 21220660 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Internet (EI)
Number of subjects: 2005
Study 21220660 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Internet plus telephone (EI+P)
Number of subjects: 2005
Study 19266579 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-anchored hearing aid (BAHA)
Number of subjects: 7
Study 19266579 — intervention group
Group type: COMPARATOR
Intervention: Directional BAHA
Number of subjects: 7
Study 19266579 — intervention group
Group type: COMPARATOR
Intervention: Omnidirectional BAHA
Number of subjects: 7
Study 20021927 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban (intravenous bolus 10 microg/kg followed by intravenous infusion of 0.15 microg/kg/min for 48 h)
Number of subjects: 157
Study 20021927 — intervention group
Group type: COMPARATOR
Intervention: saline (control group)
Number of subjects: 157
Study 15817596 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDS
Number of subjects: 143
Study 11870140 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine levels in pregnancies with fetal chromosomal abnormalities
Number of subjects: 0
Study 11870140 — intervention group
Group type: COMPARATOR
Intervention: Cytokine levels in euploid pregnancies (control group)
Number of subjects: 0
Study 11870140 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of interleukin‐8 and interleukin‐6 levels
Number of subjects: 0
Study 9871425 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg quinidine premedication
Number of subjects: 10
Study 9871425 — intervention group
Group type: COMPARATOR
Intervention: Placebo premedication
Number of subjects: 10
Study 7608829 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei subsp. casei strain GG (LGG)
Number of subjects: 49
Study 7608829 — intervention group
Group type: EXPERIMENTAL
Intervention: L. casei subsp. rhamnosus (Lactophilus)
Number of subjects: 49
Study 7608829 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Streptococcus thermophilus and L. delbrückii subsp. bulgaricus (Yalacta)
Number of subjects: 49
Study 2571860 — intervention group
Group type: EXPERIMENTAL
Intervention: CD45 monoclonal antibodies (mAbs) perfusion
Number of subjects: 77
Study 2571860 — intervention group
Group type: COMPARATOR
Intervention: Control human albumin solution
Number of subjects: 77
Study 371293 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholera chemical vaccine (2 tablets)
Number of subjects: 150
Study 371293 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholera chemical vaccine (3 tablets)
Number of subjects: 150
Study 11603909 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure stent implantation (16-20 atm)
Number of subjects: 120
Study 31434149 — intervention group
Group type: EXPERIMENTAL
Intervention: six-dose IV-TXA (total dosage more than 6 g)
Number of subjects: 175
Study 31825973 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia (SZ)
Number of subjects: 91
Study 31825973 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsessive-Compulsive Disorder (OCD)
Number of subjects: 91
Study 31825973 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 91
Study 31825973 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD
Number of subjects: 91
Study 29339393 — intervention group
Group type: EXPERIMENTAL
Intervention: Finafloxacin (300 mg b.i.d. orally for uUTI and 800 mg q.d. i.v. for cUTI/PN)
Number of subjects: 132
Study 29339393 — intervention group
Group type: EXPERIMENTAL
Intervention: Finafloxacin
Number of subjects: 132
Study 29339393 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (250 mg b.i.d. orally for uUTI and 400 mg b.i.d. i.v. for cUTI/PN)
Number of subjects: 132
Study 29339393 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 132
Study 27369316 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting posture at baseline
Number of subjects: 240
Study 27369316 — intervention group
Group type: COMPARATOR
Intervention: Face up lying down posture at baseline
Number of subjects: 240
Study 27369316 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes at a more downward angle
Number of subjects: 240
Study 25355211 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sleep with therapeutic CPAP throughout
Number of subjects: 0
Study 25355211 — intervention group
Group type: COMPARATOR
Intervention: REM disruption with CPAP reduced only in REM sleep
Number of subjects: 0
Study 22507386 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum OLB6378 (B. bifidum) administered within 48 hours of birth
Number of subjects: 36
Study 22507386 — intervention group
Group type: COMPARATOR
Intervention: Bifidobacterium bifidum OLB6378 (B. bifidum) administered more than 48 hours after birth
Number of subjects: 36
Study 20674669 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic agents for treatment of rheumatic diseases
Number of subjects: 0
Study 20674669 — intervention group
Group type: COMPARATOR
Intervention: Observational cohorts and registries
Number of subjects: 0
Study 17659971 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin 0.5% every 10 minutes for one hour before surgery
Number of subjects: 27
Study 17659971 — intervention group
Group type: COMPARATOR
Intervention: Topical ofloxacin 0.3% every 10 minutes for one hour before surgery
Number of subjects: 27
Study 16519103 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim training for 7-8 years
Number of subjects: 1625
Study 16519103 — intervention group
Group type: COMPARATOR
Intervention: Sedentary controls
Number of subjects: 1625
Study 11826589 — intervention group
Group type: EXPERIMENTAL
Intervention: Education programs
Number of subjects: 0
Study 10201739 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids pretreatment
Number of subjects: 14
Study 10201739 — intervention group
Group type: COMPARATOR
Intervention: Placebo pretreatment
Number of subjects: 14
Study 7792280 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental infarcts
Number of subjects: 50
Study 7792280 — intervention group
Group type: COMPARATOR
Intervention: Positive controls (prolonged intrauterine death and fetal artery thromboses)
Number of subjects: 50
Study 7792280 — intervention group
Group type: COMPARATOR
Intervention: Negative controls (uncomplicated pregnancies)
Number of subjects: 50
Study 7792280 — intervention group
Group type: COMPARATOR
Intervention: Internal negative control (non-infarcted tissue adjacent to infarcts)
Number of subjects: 50
Study 2118853 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA 100 mg (29.6-48.2 MU) administered over 90 min followed by intravenous heparin
Number of subjects: 0
Study 360957 — intervention group
Group type: EXPERIMENTAL
Intervention: Carticaine
Number of subjects: 120
Study 360957 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 120
Study 360957 — intervention group
Group type: EXPERIMENTAL
Intervention: Both (Carticaine and Lidocaine)
Number of subjects: 120
Study 30707938 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine before (CR-B)
Number of subjects: 39
Study 30707938 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine after (CR-A)
Number of subjects: 39
Study 30707938 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 39
Study 30382900 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D image fusion guidance
Number of subjects: 106
Study 30382900 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without 3D image fusion guidance
Number of subjects: 106
Study 27028014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermocosmetic product containing 20% azelaic acid, mandelic acid, phytic acid, 4N-butyl resorcinol, and ferulic acid
Number of subjects: 60
Study 27028014 — intervention group
Group type: EXPERIMENTAL
Intervention: Other dermocosmetic products containing azelaic acid
Number of subjects: 60
Study 24490942 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Reflection and Insight Therapy (MERIT)
Number of subjects: 0
Study 24490942 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 21912270 — intervention group
Group type: EXPERIMENTAL
Intervention: SyvekPatch NT plus manual compression
Number of subjects: 80
Study 21912270 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐Stat Dry plus manual compression
Number of subjects: 80
Study 21912270 — intervention group
Group type: COMPARATOR
Intervention: manual compression alone
Number of subjects: 80
Study 20074202 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence therapy intervention
Number of subjects: 0
Study 20074202 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management training for mental health nurses
Number of subjects: 0
Study 17342036 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography in small-size AVR group (n=17) with prosthetic aortic valves 21 mm; Peak pressure gradient at rest: 42.1 mm Hg, after dobutamine infusion: 85.1 mm Hg (P<0.05). Isovolumetric relaxation time returned to normal, significant decrease in left atrium and left ventricular diameters and volumes, LVMI decreased from 127.6±47.6 to 98.1±36.9.
Number of subjects: 30
Study 17342036 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography in large-size AVR group (n=13) with valves >21 mm; Peak pressure gradient at rest: 20.9 mm Hg, after dobutamine infusion: 54 mm Hg (P<0.05). LVMI decreased from 159.9±16.1 to 125.3±10.1.
Number of subjects: 30
Study 16359289 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary sinus (CS) pacing for 20 minutes
Number of subjects: 21
Study 11547472 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal 0.3 mg morphine plus intravenous saline (group 1)
Number of subjects: 30
Study 11547472 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 0.09 mg buprenorphine plus intrathecal saline (group 2)
Number of subjects: 30
Study 11547472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.3 mg plus intravenous buprenorphine 0.09 mg (group 3)
Number of subjects: 30
Study 9761043 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate
Number of subjects: 1120
Study 9761043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1120
Study 9761043 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate (in males with severe head injury and traumatic subarachnoid hemorrhage)
Number of subjects: 1120
Study 9761043 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in males with severe head injury and traumatic subarachnoid hemorrhage)
Number of subjects: 1120
Study 7570837 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 96
Study 7570837 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine
Number of subjects: 96
Study 3045264 — intervention group
Group type: EXPERIMENTAL
Intervention: Total abdominal radiotherapy (arm A) 2,250 rad in 20 fractions (107 patients)
Number of subjects: 257
Study 3045264 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan (arm B) 8 mg/m2/d X 4 every 4 weeks X 18 courses (106 patients)
Number of subjects: 257
Study 3045264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chromic phosphate (arm C) 10 to 20 mCi (44 patients)
Number of subjects: 257
Study 3045264 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 257
Study 31785015 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 220
Study 31785015 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (Control)
Number of subjects: 220
Study 30863027 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic fall prevention program (small robot-installed fall prevention software, personal coaching, and handbook)
Number of subjects: 64
Study 30863027 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic fall prevention program
Number of subjects: 64
Study 30863027 — intervention group
Group type: COMPARATOR
Intervention: Control group (received only handbook)
Number of subjects: 64
Study 29079949 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic Network Support Intervention (n=45)
Number of subjects: 98
Study 29079949 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control, n=53)
Number of subjects: 98
Study 25048751 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley's catheter
Number of subjects: 200
Study 25048751 — intervention group
Group type: COMPARATOR
Intervention: Cook cervical ripening balloon
Number of subjects: 200
Study 23188490 — intervention group
Group type: EXPERIMENTAL
Intervention: Asoprisnil (10 or 25 mg)
Number of subjects: 0
Study 21478070 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbosymag® (simethicone, activated charcoal, magnesium oxide)
Number of subjects: 276
Study 21478070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 19738125 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/d) with gemcitabine (1,250 mg/m² days 1 and 8) and cisplatin (75 mg/m² day 1) or carboplatin (5 x AUC, day 1)
Number of subjects: 154
Study 19738125 — intervention group
Group type: COMPARATOR
Intervention: Placebo with gemcitabine (1,250 mg/m² days 1 and 8) and cisplatin (75 mg/m² day 1) or carboplatin (5 x AUC, day 1)
Number of subjects: 154
Study 16569567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercessory prayer (informed they may or may not receive prayer)
Number of subjects: 1802
Study 16569567 — intervention group
Group type: COMPARATOR
Intervention: No intercessory prayer (informed they may or may not receive prayer)
Number of subjects: 1802
Study 16569567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercessory prayer (informed they would receive prayer)
Number of subjects: 1802
Study 16569567 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intercessory prayer, uncertain)
Number of subjects: 1802
Study 16569567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercessory prayer (certain of receiving prayer)
Number of subjects: 1802
Study 16569567 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (major events and 30-day mortality)
Number of subjects: 1802
Study 12742844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 4 mg of triamcinolone acetonide
Number of subjects: 151
Study 12742844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 11082826 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐mg nicotine gum
Number of subjects: 30
Study 11082826 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐mg nicotine gum
Number of subjects: 30
Study 11082826 — intervention group
Group type: COMPARATOR
Intervention: 0‐mg nicotine gum (placebo)
Number of subjects: 30
Study 11082826 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 30
Study 9165413 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure (Paw) increased from 0 to 20 cm H2O during inspiratory hold maneuvers.
Number of subjects: 14
Study 9165413 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure (Paw) at 20 cm H2O during inspiratory hold maneuvers.
Number of subjects: 14
Study 8181594 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg per day
Number of subjects: 200
Study 8181594 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 200
Study 2453596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (1500 mg for 2 months)
Number of subjects: 63
Study 2453596 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pyrazinamide)
Number of subjects: 63
Study 29334970 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital media-based educational intervention conducted over two months using mail, Internet, and telephone platforms.
Number of subjects: 360
Study 29334970 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 360
Study 26872868 — intervention group
Group type: COMPARATOR
Intervention: Traditional protocol (iopromide 370 mg/mL + 120 kV)
Number of subjects: 48
Study 26872868 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tube voltage (100 kV), low contrast agent concentration (270 mg/mL), and iterative reconstruction
Number of subjects: 48
Study 24611853 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT)
Number of subjects: 85
Study 24611853 — intervention group
Group type: COMPARATOR
Intervention: Freedom from Smoking (FFS)
Number of subjects: 85
Study 24330619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry beverage (450 ml daily for 10 weeks)
Number of subjects: 45
Study 24330619 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 45
Study 20630440 — intervention group
Group type: EXPERIMENTAL
Intervention: GAITRite system
Number of subjects: 24
Study 20630440 — intervention group
Group type: COMPARATOR
Intervention: Stopwatch-footfall count technique
Number of subjects: 24
Study 18522969 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief GP training session (40-min training session on referral rationale and skills)
Number of subjects: 91
Study 18522969 — intervention group
Group type: COMPARATOR
Intervention: Usual care (referral guidance by post)
Number of subjects: 91
Study 16361302 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1.2 g day(‐1))
Number of subjects: 40
Study 16361302 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo capsules)
Number of subjects: 40
Study 11970774 — intervention group
Group type: EXPERIMENTAL
Intervention: Low identifiers
Number of subjects: 0
Study 11970774 — intervention group
Group type: EXPERIMENTAL
Intervention: High identifiers
Number of subjects: 0
Study 9620360 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-gamma (100 microg/day s.c. for 21 days)
Number of subjects: 73
Study 9620360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 8929931 — intervention group
Group type: EXPERIMENTAL
Intervention: Grant Street Partnership (GSP) program
Number of subjects: 294
Study 8929931 — intervention group
Group type: COMPARATOR
Intervention: Usual services group
Number of subjects: 294
Study 8929931 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 294